skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite®

(2633) Views  (631) Full article downloads

Authors: David Granet, Steven J Lichtenstein, Bruce Onofrey, James A Katz

Published Date January 2007 Volume 2007:1(4) Pages 519 - 525
DOI: http://dx.doi.org/10.2147/OPTH.S

David Granet1, Steven J Lichtenstein2, Bruce Onofrey3, James A Katz4

1University of California at San Diego, San Diego, CA, USA; 2University of Illinois College of Medicine at Peoria and Chicago, Chicago, IL, USA; 3UC Berkeley College of Optometry, Albuquerque, NM, USA; 4The Midwest Center for Sight, Des Plaines, IL, USA

Abstract: This subject-masked, randomized, active and placebo-controlled study compared subjects’ perceptions of two antibiotic ophthalmic drops. One hundred and twenty-five healthy volunteers received two of the following solutions: moxifloxacin 0.5% ophthalmic solution (Vigamox®, Alcon Laboratories, Inc., Ft Worth, TX, USA), azithromycin 1% in DuraSite® (AzaSiteTM, Inspire Pharmaceuticals, Inc., Durham, NC, USA), or Tears Naturale II® (Alcon Laboratories, Inc., Ft. Worth, TX, USA) in contralateral eyes. Immediately following instillation and at 1, 3, 5, and 10 minutes thereafter, subjects rated comfort, acceptability, and blurring on 0–10 point analog scales stating their preference of treatment. Among subjects receiving moxifloxacin and azithromycin in contralateral eyes, 84% preferred moxifl oxacin. Moxifloxacin was rated more comfortable and acceptable with less blurring than azithromycin (p < 0.0001). These differences were observed in both the adult and pediatric populations. Ocular adverse events (redness, irritation, stinging, burning, dryness, itching and chemosis) were observed in 18 (17.3%) eyes receiving azithromycin and 1 (1%) eye receiving moxifloxacin. Moxifloxacin was significantly more tolerable than azithromycin in healthy adult and pediatric eyes. Tolerability and patient acceptance affect compliance; thus these data should be of significance to the clinician.

Keywords: moxifloxacin, azithromycin, tolerability, compliance








Readers of this article also read:

Clinical development of 1% azithromycin in DuraSite®, a topical azalide anti-infective for ocular surface therapy
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin
Editorial
Erratum
Evaluation of carboxymethylcellulose 0.5%/glycerin 0.9% and sodium hyaluronate 0.18% artificial tears in patients with mild to moderate dry eye
Erratum